Aridis Pharmaceuticals (ARDS) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aridis Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDS shares.
View ARDS analyst ratings or view top-rated stocks.

2 analysts have issued 1 year price objectives for Aridis Pharmaceuticals' stock. Their ARDS share price forecasts range from $2.00 to $10.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 1,982.6% from the stock's current price.
View analysts price targets for ARDS or view top-rated stocks among Wall Street analysts.

Aridis Pharmaceuticals' stock was trading at $1.18 at the start of the year. Since then, ARDS stock has decreased by 75.6% and is now trading at $0.2881.
View the best growth stocks for 2023 here.

Aridis Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 756,200 shares, an increase of 87.0% from the April 30th total of 404,400 shares. Based on an average trading volume of 881,700 shares, the short-interest ratio is presently 0.9 days.
View Aridis Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, June 5th 2023.
View our ARDS earnings forecast.

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) issued its earnings results on Wednesday, November, 10th. The company reported ($1.94) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $1.43. The firm earned $0.52 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aridis Pharmaceuticals investors own include Juno Therapeutics (JUNO), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Ocular Therapeutix (OCUL), Pluristem Therapeutics (PSTI) and SCYNEXIS (SCYX).

(ARDS) raised $28 million in an IPO on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor served as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers.

Aridis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARDS."

Aridis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (7.12%), Commonwealth Equity Services LLC (2.15%) and Simplex Trading LLC (0.00%). Insiders that own company stock include John F Hamilton and Vu Truong.
View institutional ownership trends.

Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDS stock can currently be purchased for approximately $0.29.

Aridis Pharmaceuticals (NASDAQ:ARDS) has a market capitalization of $10.39 million and generates $3.09 million in revenue each year. The company earns $-30,370,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis.

Aridis Pharmaceuticals' mailing address is 5941 Optical Ct, San Jose CA, 95138. The official website for the company is www.aridispharma.com. The company can be reached via phone at (408) 385-1742, via email at jwong@bplifescience.com, or via fax at 408-960-3822.